Ruxolitinib Safety Experience In The Polycythemia Vera Clinical Trial Program.

Journal of Clinical Oncology(2015)

Cited 0|Views20
No score
Abstract
e18082 Background: Polycythemia vera (PV) is associated with over-activation of the JAK/STAT pathway and characterized by erythrocytosis and an increased risk of thrombosis. Some patients (pts) may...
More
Translated text
Key words
polycythemia vera,clinical trial,clinical trial program
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined